Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

927
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

1.1K
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
1.1K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glial-modulating agents for the treatment of pain: a systematic review.

Pain·2024
Same author

Ketamine for Cancer Pain: Re. Systematic Review by Jiao et al.

Journal of pain and symptom management·2024
Same author

Effectiveness of non-pharmacological interventions for fibromyalgia and quality of review methods: an overview of Cochrane Reviews.

Seminars in arthritis and rheumatism·2023
Same author

Trials We Cannot Trust: Investigating Their Impact on Systematic Reviews and Clinical Guidelines in Spinal Pain.

The journal of pain·2023
Same author

Characteristics of retracted publications related to pain research: a systematic review.

Pain·2023
Same author

Cannabis-based medicines and medical cannabis for adults with cancer pain.

The Cochrane database of systematic reviews·2023
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

19.0K

Triptans for acute cluster headache.

Simon Law, Sheena Derry, R Andrew Moore

    The Cochrane Database of Systematic Reviews
    |December 20, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Subcutaneous sumatriptan at 6 mg effectively treats cluster headaches, offering rapid pain relief compared to placebo and other triptans. Oral or intranasal triptans showed less benefit for acute cluster headache episodes.

    More Related Videos

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
    10:39

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

    Published on: June 2, 2014

    19.1K
    Author Spotlight: Minimally Invasive Relief for Occipital Neuralgia at the Nuchal Line
    04:06

    Author Spotlight: Minimally Invasive Relief for Occipital Neuralgia at the Nuchal Line

    Published on: September 13, 2024

    4.0K

    Related Experiment Videos

    Last Updated: May 4, 2026

    Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
    09:35

    Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

    Published on: May 10, 2017

    19.0K
    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
    10:39

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

    Published on: June 2, 2014

    19.1K
    Author Spotlight: Minimally Invasive Relief for Occipital Neuralgia at the Nuchal Line
    04:06

    Author Spotlight: Minimally Invasive Relief for Occipital Neuralgia at the Nuchal Line

    Published on: September 13, 2024

    4.0K

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Cluster headache is a rare, severe, and disabling neurological condition characterized by rapid onset of intense pain.
    • Treatment options for cluster headache are limited, with inhaled oxygen being a first-line therapy.
    • Triptans, effective for migraines, are being investigated for their potential in treating cluster headaches.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of triptans for acute treatment of episodic and chronic cluster headache.
    • To compare triptans against placebo and other active interventions in adult patients.
    • To assess the effectiveness of different triptan formulations and routes of administration.

    Main Methods:

    • Systematic review of randomized, double-blind, placebo-controlled studies.
    • Searches conducted across multiple databases (CENTRAL, MEDLINE, EMBASE, ClinicalTrials.gov) up to April 2013.
    • Data extraction focused on pain relief, need for rescue medication, and adverse events; relative risk and NNT/NNH calculated.

    Main Results:

    • Subcutaneous sumatriptan 6 mg demonstrated superior efficacy compared to placebo, with 48% pain-free at 15 minutes (NNT 3.3).
    • Intranasal zolmitriptan (5 mg or 10 mg) showed less benefit than subcutaneous sumatriptan for rapid pain relief.
    • No new studies were identified in the 2013 update; all included studies used single-dose triptans for moderate to severe pain.

    Conclusions:

    • Subcutaneous sumatriptan 6 mg is more effective than intranasal zolmitriptan for rapid symptom response in cluster headache.
    • Oral administration of triptans is not considered appropriate for acute cluster headache treatment based on available data.
    • Further research may be needed to fully establish the role of triptans in cluster headache management.